← Eichor
Condition: Nhl Adult Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Nhl Adult

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Phase 1 · 7 location(s) · Marker Therapeutics, Inc. · NCT05798897A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Ly
Phase 1 · 1 location(s) · Ruijin Hospital · NCT07072169A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Phase 1 · 17 location(s) · Arvinas Inc. · NCT06393738Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
Phase 1 · 1 location(s) · University of Colorado, Denver · NCT05098613Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignanci
Phase 1 · 1 location(s) · University of Kansas Medical Center · NCT06879340A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined
Phase 3 · 168 location(s) · Regeneron Pharmaceuticals · NCT06091865Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820CAR T-cell Therapy in Patients With Renal Dysfunction
Phase 2 · 1 location(s) · Northside Hospital, Inc. · NCT05909059Novel Therapeutic Approach for Human T-cell Malignancies
Phase N/A · 2 location(s) · Istituto Oncologico Veneto IRCCS · NCT06600568Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
Phase 1/Phase 2 · 3 location(s) · Chinese PLA General Hospital · NCT06014073Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malign
EARLY_Phase 1 · 1 location(s) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. · NCT07312630Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Phase 1/Phase 2 · 1 location(s) · Medical University of South Carolina · NCT05702853Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma
Phase N/A · 20 location(s) · Fondazione Italiana Linfomi - ETS · NCT05524298A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants
Phase 1/Phase 2 · 30 location(s) · Hoffmann-La Roche · NCT05533775Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia
Phase 1/Phase 2 · 1 location(s) · Fondazione Matilde Tettamanti Menotti De Marchi Onlus · NCT05869279CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
Phase 1 · 2 location(s) · Rong Tao · NCT06445803REal World Data in LYmphoma and Survival in Adults
Phase N/A · 37 location(s) · Hospices Civils de Lyon · NCT03869619Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggr
Phase 1/Phase 2 · 6 location(s) · University of Alberta · NCT03938987SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
Phase 1/Phase 2 · 1 location(s) · University of California, San Diego · NCT072226313'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-p
EARLY_Phase 1 · 2 location(s) · Grit Biotechnology · NCT07205315Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphoma
Phase 1 · 1 location(s) · John Reneau · NCT04848064A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Ho
Phase 1 · 1 location(s) · Murdoch Childrens Research Institute · NCT06383338Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Ste
EARLY_Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06398457TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
Phase 1/Phase 2 · 3 location(s) · Chinese PLA General Hospital · NCT06323525
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.